Legis Daily

IGNITE American Innovation Act

USA117th CongressHR-3623| House 
| Updated: 5/28/2021
Dean Phillips

Dean Phillips

Democratic Representative

Minnesota

Cosponsors (2)
Jackie Walorski (Republican)John R. Curtis (Republican)

Ways and Means Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Innovation and Growth Now by Investing in Tomorrow's Enterprises Act or the IGNITE American Innovation Act This bill allows certain C corporation taxpayers to elect an increased advance refund of net operating loss carryovers attributable to COVID-19 research expenditures in 2020 and 2021. The bill also allows such taxpayers an advance refund of certain other net operating loss carryovers arising during 2015 through 2021. The bill allows an increased research tax credit for COVID-19 research expenditures paid or incurred on or after February 15, 2020, and before January 1, 2022.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-7917
IGNITE American Innovation Act
May 28, 2021
Introduced in House
May 28, 2021
Referred to the House Committee on Ways and Means.
Jul 29, 2021

Latest Companion Bill Action

S 117-2529
Introduced in Senate
  • Bill from Previous Congress

    HR 116-7917
    IGNITE American Innovation Act


  • May 28, 2021
    Introduced in House


  • May 28, 2021
    Referred to the House Committee on Ways and Means.


  • July 29, 2021

    Latest Companion Bill Action

    S 117-2529
    Introduced in Senate

Taxation

Related Bills

  • S 117-2529: IGNITE American Innovation Act
AppropriationsBusiness expensesCardiovascular and respiratory healthCorporate finance and managementDisability assistanceDrug therapyEmergency medical services and trauma careGovernment trust fundsHealth promotion and preventive careHealth technology, devices, suppliesIncome tax creditsIncome tax deductionsInfectious and parasitic diseasesMedical researchMedical tests and diagnostic methodsMedicarePrescription drugsResearch and developmentSocial security and elderly assistance

IGNITE American Innovation Act

USA117th CongressHR-3623| House 
| Updated: 5/28/2021
Innovation and Growth Now by Investing in Tomorrow's Enterprises Act or the IGNITE American Innovation Act This bill allows certain C corporation taxpayers to elect an increased advance refund of net operating loss carryovers attributable to COVID-19 research expenditures in 2020 and 2021. The bill also allows such taxpayers an advance refund of certain other net operating loss carryovers arising during 2015 through 2021. The bill allows an increased research tax credit for COVID-19 research expenditures paid or incurred on or after February 15, 2020, and before January 1, 2022.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-7917
IGNITE American Innovation Act
May 28, 2021
Introduced in House
May 28, 2021
Referred to the House Committee on Ways and Means.
Jul 29, 2021

Latest Companion Bill Action

S 117-2529
Introduced in Senate
  • Bill from Previous Congress

    HR 116-7917
    IGNITE American Innovation Act


  • May 28, 2021
    Introduced in House


  • May 28, 2021
    Referred to the House Committee on Ways and Means.


  • July 29, 2021

    Latest Companion Bill Action

    S 117-2529
    Introduced in Senate
Dean Phillips

Dean Phillips

Democratic Representative

Minnesota

Cosponsors (2)
Jackie Walorski (Republican)John R. Curtis (Republican)

Ways and Means Committee

Taxation

Related Bills

  • S 117-2529: IGNITE American Innovation Act
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
AppropriationsBusiness expensesCardiovascular and respiratory healthCorporate finance and managementDisability assistanceDrug therapyEmergency medical services and trauma careGovernment trust fundsHealth promotion and preventive careHealth technology, devices, suppliesIncome tax creditsIncome tax deductionsInfectious and parasitic diseasesMedical researchMedical tests and diagnostic methodsMedicarePrescription drugsResearch and developmentSocial security and elderly assistance